High Flow in Interstitial Lung Disease

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

June 3, 2021

Study Completion Date

June 30, 2021

Conditions
Lung Diseases, Interstitial
Interventions
DEVICE

Airvo2

Treatment with HighFlow through the Airvo2 device, 8 hours per day

OTHER

Usual care

"High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients"

Trial Locations (1)

9100

Aalborg University Hospital, Aalborg

All Listed Sponsors
collaborator

Fisher and Paykel Healthcare

INDUSTRY

lead

Aalborg University Hospital

OTHER

NCT03816722 - High Flow in Interstitial Lung Disease | Biotech Hunter | Biotech Hunter